Tropical Infectious Disease Consortium (TIDC) – Confidence in Concept 2019

Lead Research Organisation: Liverpool School of Tropical Medicine
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
 
Description Exapnding Excellence in England 'Centre for Drugs and Diagnostics'
Amount £9,843,478 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 07/2024 
End 07/2029
 
Description Expanding Excellence
Amount £9,843,478 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 07/2024 
End 07/2029
 
Description Impact Acceleration Accounts (IAA) Scheme ' Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development
Amount £306,774 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2023 
End 03/2025
 
Description Institutional Partnership Awards 'LSTM translational enabler'
Amount £300,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2023
 
Description Institutional Partnership Awards 'LSTM translational enabler'
Amount £300,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2023
 
Description MRC TIDC IAA 2022
Amount £59,081 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2023 
End 11/2024
 
Description MRC Translational and Quantitative Skills Doctoral Training Programme in Global Health
Amount £500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2025
 
Description Optimisation of a novel series of SARS-CoV-2 inhibitors
Amount £1,000,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2022 
End 03/2023
 
Description Optimising a High Efficacy Plasmodium vivax Malaria Vaccine ("OptiViVax")
Amount € 10,048,015 (EUR)
Funding ID 101080744 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 05/2023 
End 05/2028
 
Description Research England Connecting Capability Fund: Bloomsbury SET Impact Connector Consortium
Amount £1,900,000 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2022
 
Description Translational Development Fund
Amount £2,700,000 (GBP)
Organisation LifeArc 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2023 
End 03/2025
 
Description Translational and Quantitative Skills Doctoral Training Programme in Global Health
Amount £1,950,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2028
 
Description Tropical Infectious Disease Consortium (TIDC) - Confidence in Concept 2019
Amount £143,424 (GBP)
Funding ID MC_PC_19045 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2020 
End 03/2023
 
Description Tropical Infectious Disease Consortium (TIDC) - Confidence in Concept 2019
Amount £383,460 (GBP)
Funding ID MC_PC_19045 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2020 
End 03/2023
 
Description Type A
Amount $300,000 (USD)
Funding ID 2018298 
Organisation United States-Israel Binational Science Foundation 
Sector Public
Country Israel
Start 01/2019 
End 09/2023
 
Description UKRI MRC Impact Acceleration Accounts (IAA) Scheme 'Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development
Amount £306,774 (GBP)
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 03/2023 
End 03/2026
 
Description VaxHub Global
Amount £10,000,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2023 
End 02/2028
 
Description Can a simple change of crystallisation state restore or enhance the efficacy of pyrethroid insecticides for vector control? 
Organisation IVCC
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution We will apply deltamethrin to susceptible and resistant African Anopheline mosquitoes that are responsible for the majority of malarial deaths. Previous studies by New York University showed that metastable crystal forms of mosquito adulticides, such as deltamethrin, are faster in knocking down susceptible mosquitoes as compared with their more thermodynamically stable forms. Chemical resistance is complex and multi-faceted. We cannot simply expect that comparative lethalities of compounds will translate from susceptible strains of an organism to resistant strains of the same organism. We aim to characterize the lethality of our metastable forms on five pyrethroid resistant strains of An. gambiae s.l. colonised from Burkina Faso that differ in their combinations of resistance mechanism. We will use tarsal plate contact assays established in LITE at LSTM and develop dose response curves and measure speed of knockdown and mortality 24 hours post exposure for the two DM polymorphs.
Collaborator Contribution The objective of this proposal is to increase the effectiveness and speed of action of contemporary, crystalline contact mosquito adulticides, by creating more active solid phases of crystals and their carriers. Co-applicants Kahr and Ward have pioneered the systematic study of the crystallography of contact insecticides. The mechanism of action of these compounds begins with the surface chemistry at the interface between the crystal and a mosquito. We propose to use our understanding of the solid-state chemistry of contact insecticides that are more active against disease-carrying vectors. Faster acting crystalline forms have the added benefit of minimizing chemical waste and planetary exposure. Enhancing existing insecticides provides an alternative to the costly process of the development and evaluation of new chemical agents, and concurrently allows for the minimization of crystalline insecticide formulations used in the field.
Impact Shared scientific expertise, joint experimental outputs and interpretation thereof. Joint publication, currently under peer review. Plans for joint applications for further funding.
Start Year 2020
 
Description Can a simple change of crystallisation state restore or enhance the efficacy of pyrethroid insecticides for vector control? 
Organisation New York University
Country United States 
Sector Academic/University 
PI Contribution We will apply deltamethrin to susceptible and resistant African Anopheline mosquitoes that are responsible for the majority of malarial deaths. Previous studies by New York University showed that metastable crystal forms of mosquito adulticides, such as deltamethrin, are faster in knocking down susceptible mosquitoes as compared with their more thermodynamically stable forms. Chemical resistance is complex and multi-faceted. We cannot simply expect that comparative lethalities of compounds will translate from susceptible strains of an organism to resistant strains of the same organism. We aim to characterize the lethality of our metastable forms on five pyrethroid resistant strains of An. gambiae s.l. colonised from Burkina Faso that differ in their combinations of resistance mechanism. We will use tarsal plate contact assays established in LITE at LSTM and develop dose response curves and measure speed of knockdown and mortality 24 hours post exposure for the two DM polymorphs.
Collaborator Contribution The objective of this proposal is to increase the effectiveness and speed of action of contemporary, crystalline contact mosquito adulticides, by creating more active solid phases of crystals and their carriers. Co-applicants Kahr and Ward have pioneered the systematic study of the crystallography of contact insecticides. The mechanism of action of these compounds begins with the surface chemistry at the interface between the crystal and a mosquito. We propose to use our understanding of the solid-state chemistry of contact insecticides that are more active against disease-carrying vectors. Faster acting crystalline forms have the added benefit of minimizing chemical waste and planetary exposure. Enhancing existing insecticides provides an alternative to the costly process of the development and evaluation of new chemical agents, and concurrently allows for the minimization of crystalline insecticide formulations used in the field.
Impact Shared scientific expertise, joint experimental outputs and interpretation thereof. Joint publication, currently under peer review. Plans for joint applications for further funding.
Start Year 2020
 
Description Collaboration with University of Cambridge 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Dr Andrew Blagborough who kindly provided us with mosquitoes infected with mice malaria so that we could determine whether the REIMS technology we had already successfully used to age grade mosquitoes could also detect malaria infection. Dr Blagborough provided the samples, we analysed them.
Collaborator Contribution Collaboration with Dr Andrew Blagborough who kindly provided us with mosquitoes infected with mice malaria so that we could determine whether the REIMS technology we had already successfully used to age grade mosquitoes could also detect malaria infection
Impact This preliminary study demonstrated that the technology could readily distinguish between uninfected and infected mosquitoes using laboratory infected samples. This milestone having been accomplished we have now proceeded to test naturally infected mosquitoes from Burkina Faso.
Start Year 2022
 
Description Development of monoclonal antibodies towards an antigen test for Crimean-Congo Haemorrhagic Fever 
Organisation Mologic
Country United Kingdom 
Sector Private 
PI Contribution The antibodies will be developed by LSTM in collaboration with our commercial partner Mologic, a company leading the development of rapid diagnostics (https://mologic.co.uk/) with a focus on low-resource settings with Public Health England.
Collaborator Contribution The antibodies will be developed by LSTM in collaboration with our commercial partner Mologic, a company leading the development of rapid diagnostics (https://mologic.co.uk/) with a focus on low-resource settings with Public Health England.
Impact none yet
Start Year 2021
 
Description LSHTM 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution We have led the development of the collaboration with LSHTM for a consortium that includes other national HEI partners all with a focus to support pump priming activities in the translational space relevant for infections that are significant to disadvantaged populations in the UK and abroad.
Collaborator Contribution The partner is an active member of the described consortium that gives significant in kind support with respect to resource and technical expertise.
Impact Please see Research Fish for CiC and IAA awards.
Start Year 2011
 
Description Medicinal Chemistry Collaboration with Prof Matthew Fuchter. 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution We have tested novel experimental compounds for antimalarial activity.
Collaborator Contribution Medicinal chemistry support. Rational design and production of new antimalarial molecules.
Impact Outputs are in progress and not released yet.
Start Year 2020
 
Description Novavax Matrix-M adjuvant 
Organisation Novavax AB
Country Sweden 
Sector Private 
PI Contribution Vaccine development
Collaborator Contribution Matrix-M adjuvant provision
Impact Collaborative clinical vaccine development. Joint grant applications.
Start Year 2017
 
Description Recombinant bacteriophages for direct detection of bacterial blood stream infections - mew partnership with Dr Sagona (Warwick) 
Organisation University of Warwick
Department School of Life Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution This award has enabled a new partnership between my group and Antonia Sagona at Warwick. The laboratory work funded by this project has occurred in my laboratory at LSTM, and has involved the isolation and evolution of phages for diagnostic purposes. We are on track to hit our milestones, and will be publishing data and applying for further funding. I have lead monthly meetings between the two groups and have presented our data to the teams
Collaborator Contribution The Sagona lab has provided model bacteriophage to generate preliminary results, and has provided SOPs for phage isolation and characterisation. this ha sbeen key to transfer knowledge to my lab in LSTM, and has enabled us to isolate a new library of phages.
Impact The project has led to further funding via a Wellcome trust iTPA institutional senior fellowship (£74,240). This has provided follow on funding but also guidance on commercialisation of the final diagnostic test.
Start Year 2021
 
Description Rob Moon LSHTM 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution Assay setup for transgenic P. knowlesi parasites to assist vaccine testing to P. vivax.
Collaborator Contribution Development of transgenic P. knowlesi parasites to assist vaccine testing to P. vivax.
Impact Joint publication and MRC CiC funding
Start Year 2017
 
Description UKHSA 
Organisation Public Health England
Department Public Health England Porton Down
Country United Kingdom 
Sector Public 
PI Contribution We have led the development of the collaboration with UKHSA for a consortium that includes other national HEI partners all with a focus to support pump priming activities in the translational space relevant for infections that are significant to disadvantaged populations in the UK and abroad.
Collaborator Contribution The partner is an active member of the described consortium that gives significant in kind support with respect to resource and technical expertise.
Impact Please see Research Fish for CiC and IAA awards.
Start Year 2011
 
Description University of Oxford 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution We have led the development of the collaboration with Oxford for a consortium that includes other national HEI partners all with a focus to support pump priming activities in the translational space relevant for infections that are significant to disadvantaged populations in the UK and abroad.
Collaborator Contribution The partner is an active member of the described consortium that gives significant in kind support with respect to resource and technical expertise.
Impact Please see Research Fish for CiC and IAA awards.
Start Year 2011
 
Title BIOMARKERS FOR TUBERCULOSIS 
Description In one aspect, provided herein is a method for detecting tuberculosis in a subject, comprising (a) determining a level of one or more host immune system biomarkers in a sputum sample obtained from the subject; and (b) comparing the levels of the biomarkers in the sputum sample to one or more reference values; wherein the levels of the biomarkers in the sputum sample compared to the reference values are indicative of the presence or absence of tuberculosis in the subject. 
IP Reference WO2015040377 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact None to date
 
Title CRYSTALLINE FORMS OF DELTAMETHRIN AND METHODS OF USE THEREOF 
Description The present invention relates to a novel crystalline form of deltamethrin, which is a pyrethroid compound useful as a pest control agent. The present invention further relates to a process of preparing the novel crystalline form, and to methods of controlling pests using the novel crystalline form. 
IP Reference US2021092957 
Protection Patent / Patent application
Year Protection Granted 2021
Licensed Commercial In Confidence
Impact The present invention relates to a novel crystalline form of deltamethrin, which is a pyrethroid compound useful as a pest control agent. The present invention further relates to a process of preparing the novel crystalline form, and to methods of controlling pests using the novel crystalline form
 
Title PESTICIDAL COMPOUNDS AND METHODS OF USE 
Description Described herein are compounds, pesticidally acceptable salts thereof, and compositions thereof that are useful, for example, for pest management and for controlling pests. In certain embodiments provided are enantioenriched and/or enantiopure compounds and pesticidally acceptable salts thereof, and methods of making same. Methods of controlling pests with the compounds of the disclosure are also provided. 
IP Reference US2021092950 
Protection Patent / Patent application
Year Protection Granted 2021
Licensed Commercial In Confidence
Impact Described herein are compounds, pesticidally acceptable salts thereof, and compositions thereof that are useful, for example, for pest management and for controlling pests. In certain embodiments provided are enantioenriched and/or enantiopure compounds and pesticidally acceptable salts thereof, and methods of making same. Methods of controlling pests with the compounds of the disclosure are also provided.
 
Description Poster presentation at Vector Control Working Group meeting, Ghana 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Svetlana Ryazanskaya presented a poster describing the results of this work on behalf of the research team at the 5th Annual Meeting Multi-Sectoral Working Group of the Roll Back Malaria and Vector Control Working Group in Accra, Ghana on 9-11th February 2023.
https://www.globalmalariaevents.org/event/0492f559-8714-424c-97a5-fc4f5d1cef22/summary
Year(s) Of Engagement Activity 2023
URL https://www.globalmalariaevents.org/event/0492f559-8714-424c-97a5-fc4f5d1cef22/summary
 
Description Presentation at the Jenner Institute Anniversary symposium - The Royal Society, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation showcasing our work on vaccine encapsulation which attracted interest from two potential industrial partners and was followed up by further informal discussions.
Year(s) Of Engagement Activity 2023